NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
11:17
The number of deaths resulting from the earthquakes in Venezuela has risen to 6,125. Almost 1,400 people are reported missing.
11:15
Romanian firefighters return from the mission to extinguish fires in France / The third shift of the module continues missions in support of the French authorities
11:12
The Prosumers Association requests the application of 0% VAT for photovoltaic systems up to 27 kW and storage batteries.
11:05
The National Meteorological Administration extends heat alerts: Red code in several counties across the country / Temperatures up to 41 degrees
11:05
The former commander of the Ukrainian army criticized NATO for its lack of adaptation to modern warfare and questioned the prospect of Ukraine's membership.
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
